EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC 4.0

Real-world effectiveness and safety of torsemide and spironolactone fixed dose combination in Indian heart failure patients (RESTORE-HF study): a prospective, multicenter, observational study

Chandrashekhar K Ponde, Devanu Ghosh Roy, Uday Jadav, Arun Mohanty, Karan Dang, Febin Francis, Nitin Zalte, Amarnath Sugumaran iD, Sandesh Sawant, Senthilnathan Mohanasundaram

Therapeutic Advances in Cardiovascular Disease · 2026-03 · 20

DOI: 10.1177/17539447261430243 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Therapeutic Advances in Cardiovascular Disease, online erschienen am 17.03.2026. Verfasst von Chandrashekhar K Ponde und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, P. D. Hinduja Hospital, Mumbai, India. Hauptthemen laut MEDLINE: Heart Failure, Torsemide, Spironolactone, Diuretics. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: cipla.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Heart failure (HF) remains a major public health challenge in India, with a need for effective and well-tolerated therapeutic strategies.

Objective

The RESTORE-HF study evaluated the real-world effectiveness and safety of torsemide-spironolactone fixed-dose combination (FDC) in Indian patients with HF.

Design

Prospective, multicenter, observational study.

Methods

This study was conducted across 101 sites in India. Patients aged 18–75 years with HF with reduced ejection fraction and signs of congestion were enrolled and initiated on the torsemide-spironolactone FDC. Participants were followed over 3 weeks from baseline. The primary objective was the change in body weight. Secondary endpoints included changes in New York Heart Association (NYHA) functional class, edema, occurrence of adverse events (AEs), and physician and patient assessments of efficacy and tolerability.

Results

Of the 1841 patients screened, 1752 were enrolled, and 1520 completed the study. The mean (SD) age of participants was 58.61 (9.45) years, of whom 61.05% were male. The study showed a significant reduction in mean body weight was observed from 75.54 kg at baseline to 73.13 kg at week 3 (mean difference: 2.41 kg; p < 0.0001). Additionally, an improvement in NYHA functional class and edema was observed over 3 weeks from baseline. Overall, 22.11% patients achieved no-edema stage. Only three mild AEs related to loose stools were reported, and no serious AEs or deaths occurred. Over 98% of physicians and patients rated the therapy favorably.

Conclusion

The RESTORE-HF study demonstrated that the torsemide-spironolactone FDC may be associated with a mean body weight reduction of 2.41 kg and may be generally well-tolerated in Indian heart failure patients. Furthermore, the FDC may be linked to significant symptomatic improvement over 3 weeks in real-world clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureTorsemideSpironolactoneDiureticsMineralocorticoid Receptor AntagonistsSulfonamidesHumansMaleMiddle AgedProspective StudiesIndiaAgedAdultTreatment OutcomeFemaleDrug CombinationsAdolescentYoung AdultTime FactorsStroke Volume

Stichwörter der Autor:innen

Indian populationNYHA functional classdiuretic therapyfixed dose combinationheart failureshort-term outcomes

Substanzen

Drug CombinationsTorsemideSpironolactoneDiureticsMineralocorticoid Receptor AntagonistsSulfonamides

Autor:innen und Institutionen

  • Department of Cardiology, P. D. Hinduja Hospital, Mumbai, India.
  • Peerless Hospital, Kolkata, India.
  • MGM New Bombay Hospital, Vashi, New Mumbai, India.
  • Sir Ganga Ram Hospital, New Delhi, India.
  • Paras Hospital, Panchkula, Haryana, India.
  • Medical Affairs, Cipla Ltd, Mumbai, India.

ORCID-Profile: Amarnath Sugumaran

Förderung

  • cipla

Zitieren

APA

Ponde, C. K., Ghosh Roy, D., Jadav, U., Mohanty, A., Dang, K., Francis, F., Zalte, N., Sugumaran, A., Sawant, S., & Mohanasundaram, S. (2026). Real-world effectiveness and safety of torsemide and spironolactone fixed dose combination in Indian heart failure patients (RESTORE-HF study): a prospective, multicenter, observational study. Therapeutic Advances in Cardiovascular Disease, 20. https://doi.org/10.1177/17539447261430243

Vancouver

Ponde CK, Ghosh Roy D, Jadav U, Mohanty A, Dang K, Francis F, et al. Real-world effectiveness and safety of torsemide and spironolactone fixed dose combination in Indian heart failure patients (RESTORE-HF study): a prospective, multicenter, observational study. Therapeutic Advances in Cardiovascular Disease. 2026;20. doi:10.1177/17539447261430243

BibTeX
@article{Ponde2026,
  author = {Ponde, Chandrashekhar K and Ghosh Roy, Devanu and Jadav, Uday and Mohanty, Arun and Dang, Karan and Francis, Febin and Zalte, Nitin and Sugumaran, Amarnath and Sawant, Sandesh and Mohanasundaram, Senthilnathan},
  title = {Real-world effectiveness and safety of torsemide and spironolactone fixed dose combination in Indian heart failure patients (RESTORE-HF study): a prospective, multicenter, observational study},
  journal = {Therapeutic Advances in Cardiovascular Disease},
  year = {2026},
  volume = {20},
  doi = {10.1177/17539447261430243}
}
Kostenlos starten →